 

Active ingredient: Balsalazide Disodium 

 

Form/Route: Capsule/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 
Design: Single-dose, two-way crossover in-vivo 

Strength: 2250 mg dose (3 x 750 mg) 

Subjects: Normal healthy males and females, general population. Females should not be 
pregnant, and if applicable, should practice abstention or contraception during the study. 

Additional comments: 




______________________________________________________________________________ 

 

2. Type of study: Fed 
Design: Single-dose, two-way crossover in-vivo 

Strength: 2250 mg dose (3 x 750 mg) 

Subjects: Normal healthy males and females, general population 

Additional comments: Please see comment above. 




________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Balsalazide and Mesalamine in plasma 

 

Bioequivalence based on (90% CI): Balsalazide and Mesalamine 

 

Waiver request of in-vivo testing: Not Applicable 

 

In vitro dissolution testing under the following conditions should be submitted to support 
documentation of bioequivalence: 

 

Apparatus and rotation speed: USP Apparatus 1 (basket), at 100 rpm 

Medium: (1) 0.1N HCl (2) pH 4.5 buffer 

 (3) pH 6.8 buffer (4) pH 7.4 buffer 

Volume: 900 mL 

Temperature: 37ºC 

Sample times: 5, 10, 15, 20, 30, 45 and 60 minutes and until at least 80% of the 
labeled content is dissolved. 

 

Dissolution testing for stability and quality control: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website at 
http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this 
website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test 
and reference products. Specifications will be determined upon review of the application. 


